Literature DB >> 31901353

Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?

Petter Bjornstad1, Robert G Nelson2, Meda E Pavkov3.   

Abstract

Cardiovascular and renal outcome trials demonstrate nephroprotection with sodium-glucose cotransporter-2 inhibitors in people with type 2 diabetes. Attenuation of hyperfiltration is believed to be responsible for the nephroprotection, and studies in young adults with type 1 diabetes suggest that afferent arteriolar vasoconstriction induced by a tubuloglomerular feedback mechanism may be responsible for this effect. The study by van Bommel et al. suggests that this mechanism may not hold true in older adults with type 2 diabetes, who instead attenuate elevated glomerular filtration rate via post-glomerular vasodilation.
Copyright © 2019 International Society of Nephrology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31901353      PMCID: PMC7075707          DOI: 10.1016/j.kint.2019.09.023

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Single-Nephron Glomerular Filtration Rate in Healthy Adults.

Authors:  Aleksandar Denic; Jerry Mathew; Lilach O Lerman; John C Lieske; Joseph J Larson; Mariam P Alexander; Emilio Poggio; Richard J Glassock; Andrew D Rule
Journal:  N Engl J Med       Date:  2017-06-15       Impact factor: 91.245

Review 2.  Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients.

Authors:  Michael Mauer; Maria Luiza Caramori; Paola Fioretto; Behzad Najafian
Journal:  Nephrol Dial Transplant       Date:  2014-09-01       Impact factor: 5.992

3.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

4.  Patterns of renal injury in NIDDM patients with microalbuminuria.

Authors:  P Fioretto; M Mauer; E Brocco; M Velussi; F Frigato; B Muollo; M Sambataro; C Abaterusso; B Baggio; G Crepaldi; R Nosadini
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

5.  Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.

Authors:  Kengo Kidokoro; David Z I Cherney; Andrea Bozovic; Hajime Nagasu; Minoru Satoh; Eiichiro Kanda; Tamaki Sasaki; Naoki Kashihara
Journal:  Circulation       Date:  2019-02-18       Impact factor: 29.690

6.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

Review 7.  Morphologic features of declining renal function in type 1 diabetes.

Authors:  Behzad Najafian; Michael Mauer
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

Review 8.  An integrative systems biology approach for precision medicine in diabetic kidney disease.

Authors:  Skander Mulder; Habib Hamidi; Matthias Kretzler; Wenjun Ju
Journal:  Diabetes Obes Metab       Date:  2018-10       Impact factor: 6.577

  8 in total
  3 in total

Review 1.  Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte
Journal:  Nephrology (Carlton)       Date:  2021-01-04       Impact factor: 2.506

Review 2.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Tzung-Hai Yen; Kuo-Cheng Lu
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

Review 3.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.